Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Managing Negative Symptoms of Schizophrenia: How Far Have We Come?
Joshua T. Kantrowitz
CNS Drugs (2017) Vol. 31, Iss. 5, pp. 373-388
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research
Joohyun Yoon, Megan Mayer, Tala Berro, et al.
Pharmaceutical Medicine (2025)
Closed Access | Times Cited: 2
New Developments in the Treatment of Schizophrenia: An Expert Roundtable
Joshua T. Kantrowitz, Christoph U. Correll, Rakesh Jain, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 5, pp. 322-330
Open Access | Times Cited: 23
New discoveries for an old drug: a review of recent olanzapine research
Amir Mohammad Meftah, Elizabeth Deckler, Leslie Citrome, et al.
Postgraduate Medicine (2019) Vol. 132, Iss. 1, pp. 80-90
Closed Access | Times Cited: 58
Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): A replication/extension study
Joshua T. Kantrowitz, Pejman Sehatpour, Michael Avissar, et al.
Brain stimulation (2019) Vol. 12, Iss. 4, pp. 981-991
Open Access | Times Cited: 50
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers
Joshua T. Kantrowitz, Jack Grinband, Donald Goff, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 11, pp. 1842-1850
Open Access | Times Cited: 48
Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients
Joshua T. Kantrowitz, Daniel C. Javitt, Robert Freedman, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1339-1345
Open Access | Times Cited: 42
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
Joshua T. Kantrowitz
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 947-959
Closed Access | Times Cited: 39
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape
Preetika Govil, Joshua T. Kantrowitz
CNS Drugs (2025)
Closed Access
Dysbindin-1 Involvement in the Etiology of Schizophrenia
Haitao Wang, Jiangping Xu, Philip Lazarovici, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 10, pp. 2044-2044
Open Access | Times Cited: 41
The role of lumateperone in the treatment of schizophrenia
Alveena Batool Syed, James Robert Brašić
Therapeutic Advances in Psychopharmacology (2021) Vol. 11
Open Access | Times Cited: 27
Histamine H 2 receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia
Qianyi Ma, Lei Jiang, Han Chen, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 9
Open Access | Times Cited: 12
Immediate-Early Genes Modulation by Antipsychotics: Translational Implications for a Putative Gateway to Drug-Induced Long-Term Brain Changes
Andrea de Bartolomeis, Elisabetta Filomena Buonaguro, Gianmarco Latte, et al.
Frontiers in Behavioral Neuroscience (2017) Vol. 11
Open Access | Times Cited: 39
Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment
Justin Faden, Leslie Citrome
Expert Opinion on Pharmacotherapy (2018) Vol. 20, Iss. 1, pp. 11-24
Closed Access | Times Cited: 37
Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate–Type Glutamate Receptor Function
Joshua T. Kantrowitz, Neal R. Swerdlow, Walter Dunn, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2018) Vol. 3, Iss. 7, pp. 581-590
Open Access | Times Cited: 28
Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia
Maju Mathew Koola
Complex Psychiatry (2018) Vol. 4, Iss. 3, pp. 134-148
Open Access | Times Cited: 26
The Potential Role of Lumateperone—Something Borrowed? Something New?
Joshua T. Kantrowitz
JAMA Psychiatry (2020) Vol. 77, Iss. 4, pp. 343-343
Closed Access | Times Cited: 21
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058
Pejman Sehatpour, Daniel C. Javitt, Heloise M. De Baun, et al.
Neuropsychopharmacology (2021) Vol. 47, Iss. 3, pp. 711-718
Open Access | Times Cited: 20
Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia
Maju Mathew Koola, Samir Kumar Praharaj, Anilkumar Pillai
Current Behavioral Neuroscience Reports (2019) Vol. 6, Iss. 2, pp. 37-50
Open Access | Times Cited: 22
Improving cognitive training for schizophrenia using neuroplasticity enhancers: Lessons from decades of basic and clinical research
Gerson D. Guercio, Maryse E. Thomas, J. Miguel Cisneros-Franco, et al.
Schizophrenia Research (2018) Vol. 207, pp. 80-92
Closed Access | Times Cited: 21
Resting-state functional connectivity of the striatum predicts improvement in negative symptoms and general functioning in patients with first-episode psychosis: A 1-year naturalistic follow-up study
Sanghoon Oh, Minah Kim, Taekwan Kim, et al.
Australian & New Zealand Journal of Psychiatry (2019) Vol. 54, Iss. 5, pp. 509-518
Closed Access | Times Cited: 20
Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement
Maju Mathew Koola, Stephen W. Looney, Houlin Hong, et al.
Psychiatry Research (2020) Vol. 291, pp. 113285-113285
Closed Access | Times Cited: 19
How do we address treating the negative symptoms of schizophrenia pharmacologically?
Joshua T. Kantrowitz
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 14, pp. 1811-1813
Open Access | Times Cited: 16
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions
Joshua T. Kantrowitz
CNS Drugs (2021) Vol. 35, Iss. 11, pp. 1153-1161
Closed Access | Times Cited: 13
Transplantation of mesenchymal stem cells causes long-term alleviation of schizophrenia-like behaviour coupled with increased neurogenesis
Nikolai Gobshtis, Matanel Tfilin, Vadim E. Fraifeld, et al.
Molecular Psychiatry (2019) Vol. 26, Iss. 8, pp. 4448-4463
Closed Access | Times Cited: 15
Abnormalities of the Amygdala in schizophrenia: a real world study
Guang-En Zheng, Yang Zhou, Jieming Zhou, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top